quinacrine has been researched along with Creutzfeldt-Jakob Syndrome in 26 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Creutzfeldt-Jakob Syndrome: A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))
Excerpt | Relevance | Reference |
---|---|---|
"Quinacrine was administrated to a CJD patient who received a cadaveric dura mater graft and developed CJD 23 years later." | 5.32 | [Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation]. ( Hirata, K; Kobayashi, Y; Tanaka, H; Yamada, T, 2003) |
"The quinacrine-treated group, however, declined less on 2 of 3 functional scales, the modified Rankin and Clinical Dementia Rating, than the placebo group during the first 2 months." | 2.78 | Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. ( Cheng, HQ; Dearmond, SJ; Devereux, G; Duncan, JL; Finley, R; Forner, SA; Garcia, P; Geschwind, MD; Haman, A; Johnson, DY; Kuo, AL; Miller, BL; Neuhaus, JM; Possin, KL; Prusiner, SB; Raudabaugh, BJ; Thai, JN; Torres-Chae, CC; Wong, KS, 2013) |
"Quinacrine at 300 mg/day was given enterally for 3 months." | 2.71 | Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. ( Furukawa, H; Kataoka, Y; Kusuhara, T; Nakajima, M; Takahashi, M; Yamada, T; Yamauchi, A, 2004) |
"Treatment with quinacrine and chlorpromazine for acquired CJD was ineffective in our patient." | 1.33 | Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. ( Bermejo, J; Contreras, MA; Guerrero, MC; Lunar, A; Martínez Pérez, M; Martínez-Lage, JF; Rábano, A, 2005) |
"Quinacrine was administrated to a CJD patient who received a cadaveric dura mater graft and developed CJD 23 years later." | 1.32 | [Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation]. ( Hirata, K; Kobayashi, Y; Tanaka, H; Yamada, T, 2003) |
"Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD)." | 1.32 | Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. ( Alpérovitch, A; Belorgey, C; Boher, E; Brandel, JP; Delasnerie-Lauprêtre, N; Faucheux, BA; Haïk, S; Hauw, JJ; Laplanche, JL; Salomon, D; Sazdovitch, V; Soubrié, C, 2004) |
" When compared clinical effects by quinacrine and the combination therapy, improvement of clinical findings was observed at the same level without any adverse effects." | 1.32 | Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. ( Eguchi, K; Katamine, S; Kataoka, Y; Nishida, N; Niwa, M; Satoh, K; Shirabe, S; Yamauchi, A, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 23 (88.46) | 29.6817 |
2010's | 2 (7.69) | 24.3611 |
2020's | 1 (3.85) | 2.80 |
Authors | Studies |
---|---|
Miranda, LHL | 1 |
Oliveira, AFPH | 1 |
Carvalho, DM | 1 |
Souza, GMF | 1 |
Magalhães, JGM | 1 |
Júnior, JAC | 1 |
Lima, PTMBQ | 1 |
Júnior, RMA | 1 |
Filho, SPL | 1 |
Melo, HMA | 1 |
Geschwind, MD | 1 |
Kuo, AL | 1 |
Wong, KS | 1 |
Haman, A | 1 |
Devereux, G | 1 |
Raudabaugh, BJ | 1 |
Johnson, DY | 1 |
Torres-Chae, CC | 1 |
Finley, R | 1 |
Garcia, P | 1 |
Thai, JN | 1 |
Cheng, HQ | 1 |
Neuhaus, JM | 1 |
Forner, SA | 1 |
Duncan, JL | 1 |
Possin, KL | 1 |
Dearmond, SJ | 1 |
Prusiner, SB | 1 |
Miller, BL | 1 |
Teruya, K | 1 |
Doh-Ura, K | 1 |
Furukawa, H | 2 |
Takahashi, M | 2 |
Nakajima, M | 2 |
Yamada, T | 3 |
Collins, SJ | 1 |
Lewis, V | 1 |
Brazier, M | 1 |
Hill, AF | 1 |
Fletcher, A | 1 |
Masters, CL | 1 |
Follette, P | 1 |
Scoazec, JY | 1 |
Krolak-Salmon, P | 1 |
Casez, O | 1 |
Besson, G | 1 |
Thobois, S | 1 |
Kopp, N | 1 |
Perret-Liaudet, A | 1 |
Streichenberger, N | 1 |
Kobayashi, Y | 1 |
Hirata, K | 1 |
Tanaka, H | 1 |
Giles, J | 1 |
Tuma, RS | 1 |
Kusuhara, T | 1 |
Yamauchi, A | 2 |
Kataoka, Y | 2 |
Nanri, Y | 1 |
Kuroda, Y | 1 |
Butcher, J | 1 |
Brown, H | 1 |
Arruda, WO | 1 |
Bordignon, KC | 1 |
Milano, JB | 1 |
Ramina, R | 1 |
Pauri, F | 1 |
Amabile, G | 1 |
Fattapposta, F | 1 |
Pierallini, A | 1 |
Bianco, F | 1 |
Haïk, S | 1 |
Brandel, JP | 1 |
Salomon, D | 1 |
Sazdovitch, V | 1 |
Delasnerie-Lauprêtre, N | 1 |
Laplanche, JL | 1 |
Faucheux, BA | 1 |
Soubrié, C | 1 |
Boher, E | 1 |
Belorgey, C | 1 |
Hauw, JJ | 1 |
Alpérovitch, A | 1 |
Satoh, K | 1 |
Shirabe, S | 1 |
Eguchi, K | 1 |
Niwa, M | 1 |
Nishida, N | 1 |
Katamine, S | 1 |
Bertrand, A | 1 |
Martinez-Almoyna, L | 1 |
De Broucker, T | 1 |
Benito-León, J | 1 |
Martínez-Lage, JF | 1 |
Rábano, A | 1 |
Bermejo, J | 1 |
Martínez Pérez, M | 1 |
Guerrero, MC | 1 |
Contreras, MA | 1 |
Lunar, A | 1 |
Love, R | 1 |
Josefson, D | 1 |
Braunholtz, D | 1 |
Harris, J | 1 |
Cooper, E | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease[NCT00183092] | Phase 2 | 69 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition." (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | number of words generated (Mean) |
---|---|
Placebo | -2.4 |
Quinacrine | -2.2 |
ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 13.0 |
Quinacrine | 12.6 |
An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone. (NCT00183092)
Timeframe: baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | -23.2 |
Quinacrine | -13.2 |
Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 3.2 |
Quinacrine | 0.3 |
The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing. (NCT00183092)
Timeframe: Baseline to Month-2
Intervention | units on a scale (Mean) |
---|---|
Placebo | -6.9 |
Quinacrine | -3.9 |
"The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone." (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 0.8 |
Quinacrine | 0.3 |
Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | number of words generated (Mean) |
---|---|
Placebo | -3.2 |
Quinacrine | -2.2 |
Participants alive after 2 months on study treatment (NCT00183092)
Timeframe: Randomization to Month-2
Intervention | participants (Number) |
---|---|
Placebo | 19 |
Quinacrine | 13 |
4 reviews available for quinacrine and Creutzfeldt-Jakob Syndrome
Article | Year |
---|---|
Systematic review of pharmacological management in Creutzfeldt-Jakob disease: no options so far?
Topics: Aminopyridines; Creutzfeldt-Jakob Syndrome; Doxycycline; Humans; Pentosan Sulfuric Polyester; Prion | 2022 |
Insights from Therapeutic Studies for PrP Prion Disease.
Topics: Aminopyridines; Animals; Creutzfeldt-Jakob Syndrome; Disease Models, Animal; Doxycycline; Drug Disco | 2017 |
[Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine].
Topics: Animals; Antimalarials; Blood-Brain Barrier; Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; H | 2002 |
[Creutzfeldt-Jakob disease].
Topics: Antimalarials; Antipsychotic Agents; Biomarkers; Brain; Chlorpromazine; Creutzfeldt-Jakob Syndrome; | 2004 |
2 trials available for quinacrine and Creutzfeldt-Jakob Syndrome
Article | Year |
---|---|
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Creutzfeldt-Jakob Syndrome; Double-Blind Metho | 2013 |
Results of quinacrine administration to patients with Creutzfeldt-Jakob disease.
Topics: Antimalarials; Creutzfeldt-Jakob Syndrome; Electroencephalography; Eye Movements; Female; Head Movem | 2004 |
20 other studies available for quinacrine and Creutzfeldt-Jakob Syndrome
Article | Year |
---|---|
Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model.
Topics: Animals; Creutzfeldt-Jakob Syndrome; Disease Models, Animal; Enzyme Inhibitors; Female; Mice; Mice, | 2002 |
New perspectives for prion therapeutics meeting. Prion disease treatment's early promise unravels.
Topics: Animals; Brain; Brain Chemistry; Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Drug Evaluati | 2003 |
Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease.
Topics: Antimalarials; Chemical and Drug Induced Liver Injury; Creutzfeldt-Jakob Syndrome; Humans; Quinacrin | 2003 |
[Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation].
Topics: Adult; Cadaver; Creutzfeldt-Jakob Syndrome; Dura Mater; Electroencephalography; Female; Humans; Orga | 2003 |
Rapid drug trial offers hope to CJD patients.
Topics: Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Humans; Quinacrine; Time Factors; Treatment Fa | 2003 |
Drug designers seek a structural solution.
Topics: Animals; Cattle; Creutzfeldt-Jakob Syndrome; Drug Design; Quinacrine; Structure-Activity Relationshi | 2003 |
CJD researchers close to agreeing plans for first clinical trial. Arguments have marred discussions about protocol design, prompting allegations of "academic jealousy".
Topics: Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Humans; Quinacrine; Research Design | 2004 |
Fast-track CJD trial: two years late, but not derailed.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Humans; Quinacrine | 2004 |
[Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings].
Topics: Antimalarials; Antipsychotic Agents; Blotting, Western; Creutzfeldt-Jakob Syndrome; Diffusion Magnet | 2004 |
Sporadic Creutzfeldt-Jakob disease without dementia at onset: clinical features, laboratory tests and sequential diffusion MRI (in an autopsy-proven case).
Topics: 14-3-3 Proteins; Brain; Creutzfeldt-Jakob Syndrome; Dementia; Diagnosis, Differential; Diffusion Mag | 2004 |
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
Topics: Brain; Creutzfeldt-Jakob Syndrome; Disease Progression; Drug Evaluation; Humans; Quinacrine; Surviva | 2004 |
Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Creutzfeldt-Jakob Syndrome; Female; H | 2004 |
[Hereditary Creutzfeldt-Jakob disease caused by a mutation at codon 200].
Topics: 14-3-3 Proteins; Brain; Codon; Creutzfeldt-Jakob Syndrome; Electroencephalography; Enzyme Inhibitors | 2005 |
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
Topics: Adult; Brain; Chlorpromazine; Creutzfeldt-Jakob Syndrome; DNA Mutational Analysis; Dopamine Antagoni | 2005 |
Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine.
Topics: Adult; Arnold-Chiari Malformation; Cadaver; Chlorpromazine; Creutzfeldt-Jakob Syndrome; Dopamine Ant | 2005 |
Old drugs to treat new variant Creutzfeldt-Jakob disease.
Topics: Animals; Antimalarials; Antipsychotic Agents; Chlorpromazine; Creutzfeldt-Jakob Syndrome; Drug Thera | 2001 |
Drugs for malaria and psychosis may offer hope to people with CJD.
Topics: Adult; Antimalarials; Antipsychotic Agents; Chlorpromazine; Creutzfeldt-Jakob Syndrome; Female; Huma | 2001 |
Quinacrine in possible or probable CJD: if you had suspected CJD would you be indifferent between placebo and quinacrine?
Topics: Control Groups; Creutzfeldt-Jakob Syndrome; Enzyme Inhibitors; Ethics, Clinical; Humans; Quinacrine; | 2002 |
Quinacrine in possible or probable CJD: it is blinded investigators, not patients, who must be in equipoise over treatment.
Topics: Creutzfeldt-Jakob Syndrome; Enzyme Inhibitors; Ethics, Clinical; Humans; Quinacrine; Randomized Cont | 2002 |
Compassion comes before science.
Topics: Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Empathy; Humans; Quinacrine; Research Design; | 2001 |